New drug may offer safer CMV prevention for kidney transplant patients
NCT ID NCT07571135
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if letermovir works as well as valganciclovir in preventing CMV infection in 300 kidney transplant patients who are CMV-positive. Both drugs are given for 90 days after transplant. Researchers will also check if letermovir is easier to tolerate and how long it takes for infections to appear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital
San Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test could tailor CMV prevention after stem cell transplants
- Immune cells engineered to hunt viruses show promise for transplant kids
- Supercharged immune cells take on Drug-Resistant infections
- Donor cells take on Drug-Resistant viruses in new trial
- New immune duo shows promise in preventing Post-Transplant infection
- Transplant drug tweak may tame common virus